Novartis Q2 earnings exceed projections despite ongoing patent expiration headwinds

Novartis reported Q2 sales growth that surpassed market expectations, signaling a recovery from recent revenue pressures linked to U.S. patent losses. Management maintains a cautious outlook, reflecting uncertainty regarding the long-term impact of portfolio transitions.